Matrix metalloproteinase-9 expression in calcified human aortic valves: A histopathologic, immunohistochemical, and ultrastructural study

Applied Immunohistochemistry and Molecular Morphology

Volumn 24, Issue 2, 2016, Pages 128-137

  Perrotta, Ida ^a   Sciangula, Alfonso ^b   Aquila, Saveria ^a   Mazzulla, Sergio ^a  

^a UNIVERSITY OF CALABRIA   (Italy)

^b Sant'Anna Hospital   (Italy)

Author keywords

Calcific aortic valve disease (CAVD); ECM remodeling; Immunohistochemistry; MMP 9; Scanning electron microscopy (sem)

Indexed keywords

GELATINASE B;

ADULT; AORTA STENOSIS; AORTA VALVE CALCIFICATION; AORTA VALVE DISEASE; AORTA VALVE REPLACEMENT; ARTICLE; CALCIFICATION; CLINICAL ARTICLE; COLLAGEN FIBER; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; HEART MUSCLE FIBROSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYALINE CARTILAGE; IMMUNOHISTOCHEMISTRY; IMMUNOLOCALIZATION; MALE; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY); OSTEOCLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; ULTRASTRUCTURE; UPREGULATION; AORTA VALVE; AORTIC VALVE STENOSIS; CALCINOSIS; EXTRACELLULAR MATRIX; GENE EXPRESSION REGULATION; GENETICS; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE REMODELING; METABOLISM; PATHOLOGY; SCANNING ELECTRON MICROSCOPY;

AORTIC VALVE; AORTIC VALVE STENOSIS; CALCINOSIS; EXTRACELLULAR MATRIX; FEMALE; GENE EXPRESSION REGULATION; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MATRIX METALLOPROTEINASE 9; MICROSCOPY, ELECTRON, SCANNING; MIDDLE AGED; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 84958055071     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0000000000000144     Document Type: Article

References (51)

1. Boudoulas H, Vavuranakis M, Wooley CF. Valvular heart disease: the influence of changing etiology on nosology. J Heart Valve Dis. 1994;3:516-526.
2. Rajamannan NM. Calcific aortic stenosis: lessons learned from experimental and clinical studies. Arterioscler Thromb Vasc Biol. 2009;29:162-168.
3. Lee JC, Zhao XQ, Otto CM. Aortic valve sclerosis. J Echocardiogr. 2005;2:51-59.
4. Cox TR, Erler JT. Remodeling and homeostasis of the extracellular matrix: implications for fibrotic diseases and cancer. Dis Model Mech. 2011;4:165-178.
5. Wang L, Almqvist KF, Veys EM, et al. Control of extracellular matrix homeostasis of normal cartilage by a TGFbeta autocrine pathway. Validation of flow cytometry as a tool to study chondrocyte metabolism in vitro. Osteoarthritis Cartilage. 2002;10:188-198.
6. Simmons CA. Aortic valve mechanics: an emerging role for the endothelium. J Am Coll Cardiol. 2009;53:1456-1458.
7. Malemud CJ. Matrix metalloproteinases (MMPs) in health and disease: an overview. Front Biosci. 2006;11:1696-1701.
8. Perrotta I, Russo E, Camastra C, et al. New evidence for a critical role of elastin in calcification of native heart valves: immunohistochemical and ultrastructural study with literature review. Histopathology. 2011;59:504-513.
9. Rundhaug JE. Matrix metalloproteinases and angiogenesis. J Cell Mol Med. 2005;9:267-285.
10. Rosenberg GA. Matrix metalloproteinases and their multiple roles in neurodegenerative diseases. Lancet Neurol. 2009;8:205-216.
11. Nyman JS, Lynch CC, Perrien DS, et al. Differential effects between the loss of MMP-2 and MMP-9 on structural and tissue-level properties of bone. J Bone Miner Res. 2011;26:1252-1260.
12. Rybakowski JK. Matrix metalloproteinase-9 (MMP9)-a mediating enzyme in cardiovascular disease, cancer, and neuropsychiatric disorders. Cardiovasc Psychiatry Neurol. 2009;2009:7.
13. Chaudhary AK, Singh M, Bharti A, et al. Genetic polymorphisms of matrix metalloproteinases and their inhibitors in potentially malignant and malignant lesions of the head and neck. J Biomed Sci. 2010;17:10.
14. Shubayev VI, Myers RR. Matrix metalloproteinase-9 promotes nerve growth factor-induced neurite elongation but not new sprout formation in vitro. J Neurosci Res. 2004;77:229-239.
15. Cañete-Soler R, Gui YH, Linask KK, et al. Developmental expression of MMP-9 (gelatinase B) mRNA in mouse embryos. Dev Dyn. 1995;204:30-40.
16. Bergers G, Brekken R, McMahon G, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol. 2000;2:737-744.
17. Shalev E, Goldman S, Ben-Shlomo I. The balance between MMP-9 and MMP-2 and their tissue inhibitor (TIMP)-1 in luteinized granulosa cells: comparison between women with PCOS and normal ovulatory women. Mol Hum Reprod. 2001;7:325-331.
18. Barker HE, Chang J, Cox TR, et al. LOXL2-mediated matrix remodeling in metastasis and mammary gland involution. Cancer Res. 2011;71:1561-1572.
19. Salo T, Mäkelä M, Kylmäniemi M, et al. Expression of matrix metalloproteinase-2 and -9 during early human wound healing. Lab Invest. 1994;70:176-182.
20. Stevens LJ, Page-McCaw A. A secreted MMP is required for reepithelialization during wound healing. Mol Biol Cell. 2012;23:1068-1079.
21. Ortega N, Wang K, Ferrara N, et al. Complementary interplay between matrix metalloproteinase-9, vascular endothelial growth factor and osteoclast function drives endochondral bone formation. Dis Model Mech. 2010;3:224-235.
22. Li YY, Feng Y, McTiernan CF, et al. Downregulation of matrix metalloproteinases and reduction in collagen damage in the failing human heart after support with left ventricular assist devices. Circulation. 2001;104:1147-1152.
23. Liu P, Sun M, Sader S. Matrix metalloproteinases in cardiovascular disease. Can J Cardiol. 2006;22:25B-30B.
24. Yabluchanskiy A, Ma Y, Iyer RP, et al. Matrix metalloproteinase-9: many shades of function in cardiovascular disease. Physiology (Bethesda). 2013;28:391-403.
25. Wågsäter D, Zhu C, Björkegren J, et al. MMP-2 and MMP-9 are prominent matrix metalloproteinases during atherosclerosis development in the Ldlr (-/-) Apob (100/100) mouse. Int J Mol Med. 2011;28:247-253.
26. Luttun A, Lutgens E, Manderveld A, et al. Loss of matrix metalloproteinase-9 or matrix metalloproteinase-12 protects apolipoprotein E-deficient mice against atherosclerotic media destruction but differentially affects plaque growth. Circulation. 2004;109:1408-1414.
27. Shah PK, Galis ZS. Matrix metalloproteinase hypothesis of plaque rupture: players keep piling up but questions remain. Circulation. 2001;104:1878-1880.
28. Sutton MG, Sharpe N. Left ventricular remodeling after myocardial infarction. Pathophysiology and therapy. Circulation. 2000;101:2981-2988.
29. Reinhardt D, Sigusch HH, Hensse J, et al. Cardiac remodelling in end stage heart failure: upregulation of matrix metalloproteinase (MMP) irrespective of the underlying disease, and evidence for a direct inhibitory effect of ACE inhibitors on MMP. Heart. 2002;88:525-530.
30. Fondard O, Detaint D, Iung B, et al. Extracellular matrix remodelling in human aortic valve disease: the role of matrix metalloproteinases and their tissue inhibitors. Eur Heart J. 2005;26:1333-1341.
31. Kaden JJ, Vocke DC, Fischer CS, et al. Expression and activity of matrix metalloproteinase-2 in calcific aortic stenosis. Z Kardiol. 2004;93:124-130.
32. Satta J, Oiva J, Salo T, et al. Evidence for an altered balance between matrix metalloproteinase-9 and its inhibitors in calcific aortic stenosis. Ann Thorac Surg. 2003;76:681-688.
33. Soini Y, Satta J, Maatta M, et al. Expression of MMP2, MMP9, MT1-MMP, TIMP1, and TIMP2 mRNA in valvular lesions of the heart. J Pathol. 2001;94:225-231.
34. Edep ME, Shirani J, Wolf P, et al. Matrix metalloproteinase expression in nonrheumatic aortic stenosis. Cardiovasc Pathol. 2000;9:281-286.
35. Yeghiazaryan K, Skowasch D, Bauriedel G, et al. Could activated tissue remodeling be considered as early marker for progressive valve degeneration? Comparative analysis of checkpoint and ECM remodeling gene expression in native degenerating aortic valves and after bioprosthetic replacement. Amino Acids. 2007;32:109-114.
36. Rajamannan NM, Gersh B, Bonow RO. Calcific aortic stenosis: from bench to the bedside-emerging clinical and cellular concepts. Heart. 2003;89:801-805.
37. Freeman RV, Otto CM. Spectrum of calcific aortic valve disease: pathogenesis, disease progression, and treatment strategies. Circulation. 2005;111:3316-3326.
38. Rajamannan NM. Calcific aortic valve disease: cellular origins of valve calcification. Arterioscler Thromb Vasc Biol. 2011;31:2777-2778.
39. Kaden JJ, Dempfle CE, Grobholz R, et al. Inflammatory regulation of extracellular matrix remodeling in calcific aortic valve stenosis. Cardiovasc Pathol. 2005;14:80-87.
40. Wiltz D, Arevalos CA, Balaoing LR, et al. Extracellular matrix organization, structure, and function. In Calcific Aortic Valve Disease. (edited by E. Aikawa), ISBN: 978-953-51-1150-4, In Tech. (2013).
41. Yip CY, Simmons CA. The aortic valve microenvironment and its role in calcific aortic valve disease. Cardiovasc Pathol. 2011;20:177-182.
42. Sun J. Matrix metalloproteinases and tissue inhibitor of metalloproteinases are essential for the inflammatory response in cancer cells. J Signal Transduct. 2010;2010:985132.
43. Chen NX, O'Neill KD, Chen X, et al. Activation of arterial matrix metalloproteinases leads to vascular calcification in chronic kidney disease. Am J Nephrol. 2011;34:211-219.
44. Lehrke M, Greif M, Broedl UC, et al. MMP-1 serum levels predict coronary atherosclerosis in humans. Cardiovasc Diabetol. 2009;8:50.
45. Bouvet C, Moreau S, Blanchette J, et al. Sequential activation of matrix metalloproteinase 9 and transforming growth factor beta in arterial elastocalcinosis. Arterioscler Thromb Vasc Biol. 2008;28:856-862.
46. Peterson JT, Hallak H, Johnson L, et al. Matrix metalloproteinase inhibition attenuates left ventricular remodeling and dysfunction in a rat model of progressive heart failure. Circulation. 2001;103:2303-2309.
47. Pai AS, Giachelli CM. Matrix remodeling in vascular calcification associated with chronic kidney disease. J Am Soc Nephrol. 2010;21:1637-1640.
48. Ronchetti I, Boraldi F, Annovi G, et al. Fibroblast involvement in soft connective tissue calcification. Front Genet. 2013;4:22.
49. Simsa S, Genina O, Ornan EM. Matrix metalloproteinase expression and localization in turkey (Meleagris gallopavo) during the endochondral ossification process. J Anim Sci. 2007;85:1393-1401.
50. Vu TH, Werb Z. Matrix metalloproteinases: effectors of development and normal physiology. Genes Dev. 2000;14:2123-2133.
51. Rajamannan NM. Update on the pathophysiology of aortic stenosis. Eur Heart J Suppl. 2008;10:E4-E10.